PD-L2/B7-DC/PDCD1LG2 Antibody (1054620) [Alexa Fluor® 350]

• Reactivity: Hu
• Applications: B/N
• Clone: 1054620
• Clonality: Monoclonal
• Host: Mouse
• Conjugate: Alexa Fluor 350

PD-L2/B7-DC/PDCD1LG2 Antibody (1054620) [Alexa Fluor® 350] Summary

• Immunogen: Human embryonic kidney cell, HEK293-derived recombinant human PD-L2/B7-DC
  Accession # Q9BQ51
• Specificity: Detects human PD-L2/B7-DC in direct ELISA.
• Isotype: IgG1
• Clonality: Monoclonal
• Host: Mouse
• Purity Statement: Protein A or G purified

Applications/Dilutions

• Dilutions:
  • Blockade of Receptor-ligand Interaction

Packaging, Storage & Formulations

• Storage: Protect from light. Do not freeze. 12 months from date of receipt, 2 to 8 °C as supplied
• Buffer: Supplied 0.2mg/ml in 1X PBS with RDF1 and 0.09% Sodium Azide

Notes

This product is produced by and ships from R&D Systems, Inc., a Bio-Techne brand.

Alternate Names for PD-L2/B7-DC/PDCD1LG2 Antibody (1054620) [Alexa Fluor® 350]

• B7-DC
• bA574F11.2
• Btdc
• Butyrophilin B7-DC
• Butyrophilin-like Protein
• CD273 antigen
• CD273
• CD273PD-1 ligand 2
• MGC142240
• PD-1-ligand 2
• PDCD1L2MGC142238
• PDCD1LG2
• PDL2
• PD-L2
• PDL2B7DC
• PD-L2PDCD1 ligand 2
• programmed cell death 1 ligand 2
• Programmed death ligand 2

Background

Programmed Death Ligand 2 (PD-L2), also known as B7-DC and butyrophilin-like protein, is a member of the B7 family of proteins that provide signals for regulating T-cell activation and tolerance (1). Mature human PD-L2 consists of a 201 amino acid (aa) extracellular domain (ECD) with one V-like and one C-like Ig domain, a 21 aa transmembrane segment, and a 32 aa cytoplasmic domain (2, 3). Within the ECD, mouse and human PD-L2 share 72% aa sequence identity. Alternative splicing generates additional isoforms that lack the second Ig-like domain and may be substituted and truncated following the first Ig-like domain (4). PD-L2 is expressed on dendritic cells, subsets of activated CD4⁺ and CD8⁺ T cells, and memory B cells that differentiate into plasma cells (3, 5, 6). At inflammatory sites such as rheumatoid arthritis, allergen exposure, and virus infection, PD-L2 is up-regulated on synoviocytes, infiltrating macrophages, dendritic cells, and airway epithelial cells (7-11). PD-L2, along with B7-H1/PD-L1, binds to T cell PD-1 where it promotes IFN-gamma production and CD40 Ligand up-regulation while inhibiting IL-4 production (2, 3, 12, 13). In addition, PD-L2 binds to RGM-B on macrophages and alveolar epithelial cells, supporting respiratory immune tolerance (14). In asthma, PD-L2 suppresses IL-5 and IL-13 production, promotes IL-12 production by dendritic cells, and supports allergen-induced airway hyper-responsiveness and mucus production (9, 11).

Limitations

This product is for research use only and is not approved for use in humans or in clinical diagnosis. Primary Antibodies are guaranteed for 1 year from date of receipt.